Heuron Appoints Leading Stroke Experts as Clinical Advisors

Jun. 2025

Boston Medical Center’s Dr. Thanh Nguyen and Dr. Mohamad Abdalkader Join Heuron

Extensive Publications in NEJM, Lancet, and JAMA

Expected to Drive Advancement of Heuron StroCare Suite™


 

Heuron Inc. (CEO Donghoon Shin), a medical AI company specializing in neurological disorders, has appointed two leading stroke specialists—Dr. Thanh Nguyen and Dr. Mohamad Abdalkader of Boston Medical Center—as Clinical Advisors for the Heuron StroCare Suite™.

 

Dr. Nguyen is a neurologist and Director of Interventional Neurology and Neuroradiology at Boston Medical Center. She also serves as a Professor of Neurology, Neurosurgery, and Radiology at Boston University Chobanian & Avedisian School of Medicine, and is currently President of the Society of Vascular and Interventional Neurology (SVIN). She is Associate Editor of the journal Stroke and plays key leadership roles in global stroke research.

 

As a trailblazer in interventional stroke care, Dr. Nguyen has led numerous large-scale clinical trials including PICASSO and SUMMIT MAX. Her research spans endovascular thrombectomy (EVT), neuroprotection, adjunctive pharmacotherapy, and neuroimaging protocols. She has published over 450 peer-reviewed articles in top-tier journals such as The New England Journal of Medicine (NEJM), The Lancet, and JAMA. She also contributes to national stroke treatment guidelines, underscoring her clinical leadership.

 

Dr. Abdalkader is a diagnostic and interventional neuroradiologist at Boston Medical Center and Associate Professor of Radiology at Boston University Chobanian & Avedisian School of Medicine.

 

Renowned for his expertise in advanced neurovascular imaging, Dr. Abdalkader has led research on CT-based triage, acute stroke care, aneurysms, and vascular malformations. He has authored over 200 publications and serves as a reviewer and associate editor for several major journals. He is frequently invited to speak at international neurovascular and radiology conferences and is actively involved in global imaging initiatives.

 

Both Dr. Nguyen and Dr. Abdalkader participated in the multinational CLEAR study (CT for Late Endovascular Reperfusion), with Dr. Nguyen serving as principal investigator. Their clinical and academic leadership is expected to accelerate the development and optimization of Heuron StroCare Suite™, ensuring its alignment with real-world clinical demands.

 

As Clinical Advisors, they will provide strategic guidance to validate and enhance the Heuron StroCare Suite™, particularly in improving patient selection for thrombectomy and enabling better stroke outcomes through AI-powered decision support.

 

“We are honored to welcome two globally recognized stroke experts to our Clinical Advisory Board,” said Donghoon Shin, CEO of Heuron. “Their insights and research excellence will be instrumental in strengthening the clinical precision and impact of our stroke diagnostic solutions.”

 

Earlier this year, Heuron also appointed Professor Chan Ling Ling, a leading Parkinson’s disease expert in Singapore, further expanding the company’s global advisory network in neurological care.

TOP